<DOC>
	<DOCNO>NCT00002262</DOCNO>
	<brief_summary>To evaluate tolerance , toxicity , preliminary evidence antitumor efficacy intralesionally administer tumor necrosis factor ( TNF ) define maximum tolerate dose ( MTD ) single intralesional injection . In addition , assess effect TNF injection Kaposi 's sarcoma ( KS ) lesion measure P-32 magnetic resonance spectroscopy .</brief_summary>
	<brief_title>A Phase I/II Study Intralesional Recombinant Tumor Necrosis Factor Patients With AIDS-Related Cutaneous Kaposi 's Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Patients must : Biopsyproven Kaposi 's sarcoma ( KS ) multiple cutaneous lesion . Minimum life expectancy 3 month . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Clinically significant cardiac disease . Known hemorrhagic diathesis active bleeding disorder . Clinically apparent vascular disease . Known lipoprotein disorder . History seizure disorder central nervous system ( CNS ) metastasis . Additional malignancy . Concurrent Medication : Excluded : Cardiac agent . Anticoagulants . Thrombolytic agent . Nonsteroidal antiinflammatory drug . Corticosteroids . Aspirin . Vasodilators . Patients follow exclude : Additional malignancy condition list Patient Exclusion CoExisting Conditions . Prior Treatment : Excluded within 4 week study entry : Chemotherapy . Radiotherapy . Immunotherapy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 1988</verification_date>
	<keyword>Skin Neoplasms</keyword>
	<keyword>Tumor Necrosis Factor</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>